Opinion|Videos|May 1, 2024
New Therapeutic Frontiers in PAH
Author(s)Ronald Oudiz, MD, FACP, FACC, FCCP
A cardiovascular specialist provides an overview of emerging therapies and targets in the PAH treatment space and how they address current unmet needs.
Episodes in this series
Video content above is prompted by the following questions:
- What new therapeutic options have emerged in the pulmonary arterial hypertension (PAH) treatment landscape, and what are their mechanisms of action and potential benefits?
- How do emerging therapies address the unmet needs in PAH management, such as improving symptom control, slowing disease progression, or targeting specific pathways?
Related to this article
HYPERION trial data shows a 76% reduction in clinical worsening events among adults recently diagnosed with PAH.
Trending on AJMC
1
Health System Pharmacies Keep Patients on GLP-1 Therapy
2
Peptide Regulation Debate Intensifies After FDA Advisory Panel's Controversial Vote
3
Melatonin Use Linked to Small REM Sleep Reduction in Children
4
Opposing Sides of 340B Debate Converge on Data Clearinghouse, Patient Definition
5